Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Blockbuster weight loss jabs relied on by millions of slimmers could slash the risk of developing dementia, two major studies have suggested. Semaglutide — the powerful ingredient behind Wegovy ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...

Novo Nordisk A/S. NVO has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.. What ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...

It found most drugs 'were not associated with an overall reduction in all-cause dementia' although 'GLP-1RAs was associated with a statistically significant reduction in all-cause dementia.' ...